Objective:Tocompare the clinical efficacyand safety of oral administration of BuxueYimuPills(BYP),ferrous sulfate(FS),and the combination of BYP and FS on gynecological anemia,and investigate the mechanisms using netw...Objective:Tocompare the clinical efficacyand safety of oral administration of BuxueYimuPills(BYP),ferrous sulfate(FS),and the combination of BYP and FS on gynecological anemia,and investigate the mechanisms using network pharmacology.Methods:A randomized,controlled,multi-center clinical trial was conducted.Totally 150 patients with hemoglobin of 70-110 g/L due to gynecological conditions were recruited and randomized(using the block randomization method)into Buxue Yimu Pills group(24 g/d),oral iron group(FS Tablets,0.9 g/d),and combined treatment group(BYP,24g/d plus FS Tablets,0.9 g/d),50 patients in each group.At the enrollment and 4-week treatment,complete blood count,serum iron indexes were evaluated.Adverse events,liver and renal functions,as well as blood coagulation were observed.Network pharmacology was conducted to identify the active ingredients and explore the potential mechanisms of BYP.Results:Ten(20%)and 7(14%)participants discontinued the therapy due to gastrointestinal symptoms in oral iron and combination treatment groups.All 3 groups showed elevated hemoglobin.The patients in the iron group exhibited typically elevated in serum iron and ferritin and decreased in total iron-binding capacity.No change in iron indexes was observed in BYP group.The patients in the combination treatment group neither showed significant changes in serum ferritin nortotal iron-binding capacity.No significant adverse reactions were observed in the BYP group.The network pharmacology identified 27 bioactive compounds and 145 targets of BYP on gynecological anemia.Biological processes and pathways including regulation of inflammation,hormone,angiogenesis and hemostasis,responsetodecreased oxygen levels,effects on myeloma cell,and responseto metal ions were identified.Conclusion:BYP contributes to the practical improvement on gynecological anemia potentially through multi-target mechanisms and optimized iron re-distribution.展开更多
文摘Objective:Tocompare the clinical efficacyand safety of oral administration of BuxueYimuPills(BYP),ferrous sulfate(FS),and the combination of BYP and FS on gynecological anemia,and investigate the mechanisms using network pharmacology.Methods:A randomized,controlled,multi-center clinical trial was conducted.Totally 150 patients with hemoglobin of 70-110 g/L due to gynecological conditions were recruited and randomized(using the block randomization method)into Buxue Yimu Pills group(24 g/d),oral iron group(FS Tablets,0.9 g/d),and combined treatment group(BYP,24g/d plus FS Tablets,0.9 g/d),50 patients in each group.At the enrollment and 4-week treatment,complete blood count,serum iron indexes were evaluated.Adverse events,liver and renal functions,as well as blood coagulation were observed.Network pharmacology was conducted to identify the active ingredients and explore the potential mechanisms of BYP.Results:Ten(20%)and 7(14%)participants discontinued the therapy due to gastrointestinal symptoms in oral iron and combination treatment groups.All 3 groups showed elevated hemoglobin.The patients in the iron group exhibited typically elevated in serum iron and ferritin and decreased in total iron-binding capacity.No change in iron indexes was observed in BYP group.The patients in the combination treatment group neither showed significant changes in serum ferritin nortotal iron-binding capacity.No significant adverse reactions were observed in the BYP group.The network pharmacology identified 27 bioactive compounds and 145 targets of BYP on gynecological anemia.Biological processes and pathways including regulation of inflammation,hormone,angiogenesis and hemostasis,responsetodecreased oxygen levels,effects on myeloma cell,and responseto metal ions were identified.Conclusion:BYP contributes to the practical improvement on gynecological anemia potentially through multi-target mechanisms and optimized iron re-distribution.
